SwazilandTuberculosis profile
Population  2014 1.3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.65 (0.4–0.95) 51 (32–75)
Mortality (HIV+TB only) 1.7 (1.2–2.4) 135 (91–187)
Prevalence  (includes HIV+TB) 7.7 (4.3–12) 605 (337–951)
Incidence  (includes HIV+TB) 9.3 (6.8–12) 733 (533–963)
Incidence (HIV+TB only) 5.9 (4.2–7.9) 464 (330–619)
         
Case detection, all forms (%) 60 (46–83)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 7.7 (4.8–11) 34 (28–39)
MDR-TB cases among notified pulmonary
TB cases
320 (200–440) 120 (100–140)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 540   322
Pulmonary, clinically diagnosed 1 606    
Extrapulmonary 765   350
       
Total new and relapse 5 583    
Previously treated, excluding relapses 33    
Total cases notified 5 616    
Among 5 583 new and relapse cases:
502 (9%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     358
Patients started on MDR-TB treatment ***     380
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 430 (97)
HIV-positive TB patients 3 972 (73)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 904 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 3 123 (79)
HIV-positive people screened for TB 110 370  
HIV-positive people provided with IPT 1 188  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (75) 7 191
Previously treated cases, excluding relapse, registered in 2013 (66) 538
HIV-positive TB cases, all types, registered in 2013 (71) 5 773
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population)  
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available?  
Financing TB control 2015  
National TB programme budget (US$ millions) 15
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-27 Data: www.who.int/tb/data